Archives
Rotigotine: Dopamine D2/D3 Receptor Agonist for Parkinson...
Rotigotine: Dopamine D2/D3 Receptor Agonist for Parkinson's Disease Research
Executive Summary: Rotigotine is a non-ergoline dopamine receptor full agonist with high affinity for D2 and D3 receptors, also acting on D1, D4, D5, and 5-HT1A receptors, and antagonizing α2B adrenergic receptors (APExBIO). It demonstrates neuroprotective and antioxidant properties, ameliorates both motor and non-motor symptoms in Parkinson's disease (PD) and restless legs syndrome (RLS), and displays potential antidepressant activity (Bertaina-Anglade et al., 2006). Rotigotine is validated in diverse PD models, including 6-OHDA and MPTP, with defined dosing ranges and assay conditions. Its mechanism involves dopaminergic receptor activation, oxidative stress reduction, and anti-inflammatory actions. APExBIO provides research-grade Rotigotine (SKU: A3776) for validated in vitro and in vivo applications.
Biological Rationale
Parkinson's disease is characterized by degeneration of nigrostriatal dopaminergic neurons, resulting in both motor and non-motor symptoms. Dopamine D2 and D3 receptor agonists are established as key modulators of these pathways, directly addressing dopaminergic deficits (Contrast: This article specifically details Rotigotine's receptor spectrum and application parameters, expanding on the general overview in this linked resource.). Rotigotine, as a non-ergoline dopamine agonist, provides an alternative to ergot derivatives, reducing risks of fibrosis and other adverse effects. Its affinity for multiple dopamine receptor subtypes, as well as serotonergic and adrenergic targets, underpins its broad efficacy in PD and RLS models. Rotigotine addresses both motor dysfunction and neuropsychiatric comorbidities, including depression, frequently observed in PD patients (Bertaina-Anglade et al., 2006).
Mechanism of Action of Rotigotine
Rotigotine is a full agonist at dopamine D2 and D3 receptors and exhibits activity at D1, D4, and D5 receptors. It also functions as a 5-HT1A receptor agonist and an α2B adrenergic receptor antagonist. The compound exerts its antiparkinsonian and neuroprotective effects through:
- Direct stimulation of postsynaptic dopamine receptors, compensating for dopaminergic neuron loss (APExBIO).
- Reduction of oxidative stress by increasing superoxide dismutase (SOD) activity and decreasing reactive oxygen species (ROS) in neuronal tissues.
- Attenuation of inflammatory mediators, contributing to neuroprotection.
- Enhancement of dopaminergic signaling pathways, improving both locomotor and non-motor (cognitive and affective) outcomes in PD models.
- Agonist action at the 5-HT1A receptor, which may contribute to antidepressant effects (Bertaina-Anglade et al., 2006).
These mechanisms position Rotigotine as a versatile dopaminergic signaling pathway modulator in both basic and translational neuroscience research (Contrast: While previous work emphasizes translational applications, this article details precise mechanistic and experimental parameters.).
Evidence & Benchmarks
- Rotigotine increases spontaneous motor activity in rodent models at 5 mg/kg after 3–5 days of repeated administration (Bertaina-Anglade et al., 2006).
- At 0.5–5 mg/kg/day for 5 days, Rotigotine reverses active avoidance deficits in learned helplessness depression models (Bertaina-Anglade et al., 2006).
- Forced swim (behavioral despair) test indicates enhanced mobility at 5 mg/kg, suggesting antidepressant activity (Bertaina-Anglade et al., 2006).
- In vitro, 5 μg/mL Rotigotine confers neuroprotection in SH-SY5Y neuroblastoma cells (APExBIO).
- Clinical transdermal patch dosing ranges from 1 to 16 mg/24 h for PD and RLS symptom management (APExBIO).
- Rotigotine's effectiveness in 6-OHDA and MPTP-induced PD models is well-documented, supporting its role as a reference compound in dopaminergic pathway research (Contrast: This article provides updated dosing and delivery strategies, extending the discussion on advanced PD models.).
Applications, Limits & Misconceptions
Rotigotine is widely used in:
- Parkinson's disease research (motor symptom relief, neuroprotection studies).
- Restless legs syndrome models.
- Cell-based assays for dopamine receptor activity and cytotoxicity (e.g., SH-SY5Y cells, 2.5–25 μg/mL).
- Depression models (olfactory bulbectomy, learned helplessness, forced swim).
- Studies on PD-related overactive bladder and other non-motor symptoms.
- Formulation research (e.g., nanoparticle-mediated intranasal delivery at 2 mg/kg).
Common Pitfalls or Misconceptions
- Rotigotine is not effective in models where dopaminergic signaling is not a primary deficit (e.g., non-dopaminergic neurodegeneration).
- High doses (>5 mg/kg in rodents) may increase general locomotor activity, confounding behavioral readouts rather than specifically reversing depressive or parkinsonian symptoms (Bertaina-Anglade et al., 2006).
- The transdermal patch is not suitable for rodent studies due to poor skin permeation and rapid hair growth (Bertaina-Anglade et al., 2006).
- Rotigotine is insoluble in water; improper solvent use can affect assay outcomes (APExBIO).
- As a multi-receptor ligand, Rotigotine effects may involve serotonergic and adrenergic pathways—interpret specificity with caution.
Workflow Integration & Parameters
Researchers should select Rotigotine concentrations and dosing regimens based on experimental context:
- In vitro: 5 μg/mL for neuroprotection (SH-SY5Y cells), 2.5–25 μg/mL for cytotoxicity.
- In vivo: 0.05–5 mg/kg/day subcutaneous; 0.125–0.5 mg/kg intravenous; 2 mg/kg (nanoparticle, intranasal).
- Clinical research: 1–16 mg/24 h transdermal patch (not recommended for rodent models).
- Solubility: ≥58 mg/mL in DMSO; ≥25.25 mg/mL in ethanol; insoluble in water.
- Storage: -20°C, crystalline solid, molecular weight 315.47, C19H25NOS.
For validated protocols, APExBIO's A3776 Rotigotine kit offers batch-tested compound and technical support.
Conclusion & Outlook
Rotigotine is a benchmark dopamine receptor agonist for basic and translational Parkinson's disease research. Its multi-receptor activity profile, antioxidant and anti-inflammatory actions, and validated performance in both in vitro and in vivo models support its ongoing utility in neuroscience. Researchers should select concentrations and administration routes appropriate to their specific model. For further mechanistic and translational insights, see recent reviews on strategic dopaminergic modulation.